大动脉狭窄和动脉样硬化之间的共同风险因素和分子机制:治疗重新定位的理由
Corina Cinezan1,2, Dan Claudiu Magureanu3,4, Maria Luiza Hiceag5,6
1Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
International journal of molecular sciences
|September 13, 2025
概括
大动脉狭窄 (AS) 和动脉样硬化有共同的风险因素和分子途径. 用于动脉样硬化治疗的重用药物可能为AS提供新的治疗方法,改善患者的治疗结果.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 翻译科学 翻译科学
背景情况:
- 大动脉狭窄 (AS) 和动脉样硬化是常见的心血管疾病,具有共同的临床和分子特征.
- 与动脉样硬化不同的是,AS的有效药理治疗方法有限.
- 调查共享机制可能会揭示AS的治疗重新定位机会.
研究的目的:
- 审查重叠的风险因素,病理机制和AS和动脉样硬化的潜在治疗策略.
- 探索基于共享途径的AS管理现有药物类别的重新用途的潜力.
主要方法:
- 对2005年至2025年间发表的研究进行了叙述性审查.
- 包括临床试验,实验模型和分子研究,重点关注AS和动脉样硬化的共同方面.
- 分析了常见的风险因素,分子通路 (炎症,氧化应激,脂质积累,化) 和信号通路 (RAS,Notch).
主要成果:
- 确定了共同的风险因素:年龄,高血压,高脂血症和糖尿病.
- 突出了常见的分子机制:慢性炎症,内皮功能障碍,氧化应激,脂质积累和性重塑.
- 已知潜在的药物类别用于重新定位:PCSK9抑制剂,Lp (a) 降低疗法,抗炎药物和免疫调节剂.
结论:
- 在AS和动脉样硬化之间风险因素和分子途径的显著重叠为治疗重新定位提供了强有力的理由.
- 准共享的分子通路可能会导致新的策略来减缓AS的进展.
- 重用药物可以改善治疗选择和对大动脉狭窄患者的治疗结果.
相关概念视频
01:26Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
01:30Coronary Artery Disease I: Introduction
890
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
890
01:30Atherosclerosis I: Introduction
925
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
925
01:25Aortic Regurgitation III: Medical Management
399
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
399
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
474
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
474
01:26Coronary Artery Disease II: Pathophysiology
375
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
375